Assessing Seven-Year Valve Durability in the PARTNER 3 Trial
-
By
-
Dritan Useini
-
November 1, 2026
Objective:
To raise methodological and clinical considerations about interpreting seven-year valve durability comparisons between TAVR and SAVR in the PARTNER 3 analysis.
Approach:
- Comparison design: The analysis compared the SAPIEN 3 transcatheter valve with a heterogeneous group of surgical bioprostheses.
- Context cited: The letter refers to evidence of variation in durability and performance among both surgical and transcatheter valve platforms, including earlier PARTNER analyses.
- Treatment considerations: The authors discuss lifetime valve management in younger patients, including durability, reintervention, coronary access, hemodynamic performance, and mechanical prostheses.
Key Findings:
- Surgical bioprostheses vary in structural valve deterioration, hemodynamic performance, and durability.
- The cited meta-analysis found no consistent class effect across transcatheter valves; earlier PARTNER analyses reported differing structural valve deterioration rates between SAPIEN XT and SAPIEN 3.
- Comparing one transcatheter platform with pooled surgical prostheses makes it difficult to distinguish treatment-strategy effects from valve-specific effects.
- Mechanical prostheses are described as an important surgical option for selected young, low-risk patients willing and able to take lifelong anticoagulation.
Interpretation:
The letter argues that long-term performance may be valve-specific rather than procedure-specific and that comparing one transcatheter platform with pooled surgical prostheses complicates attribution of differences to the treatment strategy. It calls for greater emphasis on head-to-head evaluation of individual valve platforms.
Limitations:
- The source is a letter discussing methodological concerns, not a report of new comparative outcome data.
- The supplied context does not provide numerical results from the seven-year analysis or the cited studies.
Conclusion:
The authors argue that discussions of valve selection for younger patients should consider transcatheter, surgical bioprosthetic, and mechanical options in light of lifetime management needs.
Sources:
Based on findings from:
Interpreting 7-Year Valve Durability in PARTNER 3
Dritan Useini. Jama Cardiology, 2026.
https://jamanetwork.com/journals/jamacardiology/fullarticle/2854526
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.